Cipla CEO: Tariff Threat Won’t Impact Q4 Growth Cipla, the pharmaceutical giant, revealed that its profit for Q4 FY25 has risen by 30% compared to the previous year. The CEO has addressed concerns about short-term challenges related to U.S. regulatory … Continue reading Cipla CEO: Tariff Threat Won’t Impact Q4 Growth